Raffles Associates LP Lineage Cell Therapeutics, Inc. Transaction History
Raffles Associates LP
- $81.5 Million
- Q2 2025
A detailed history of Raffles Associates LP transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Raffles Associates LP holds 5,392,088 shares of LCTX stock, worth $5.45 Million. This represents 6.02% of its overall portfolio holdings.
Number of Shares
5,392,088
Previous 5,642,088
4.43%
Holding current value
$5.45 Million
Previous $2.54 Million
93.3%
% of portfolio
6.02%
Previous 3.45%
Shares
16 transactions
Others Institutions Holding LCTX
# of Institutions
142Shares Held
106MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$50.1 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$9.66 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$8.57 Million0.0% of portfolio
-
Defender Capital, Llc.6.79MShares$6.85 Million2.42% of portfolio
-
Comerica Bank4.6MShares$4.65 Million0.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $171M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...